InvestorsHub Logo
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

Re: willyw post# 1803

Thursday, 09/26/2019 3:08:38 PM

Thursday, September 26, 2019 3:08:38 PM

Post# of 2933

I harken back to Viekira. What if ENTA had thrown in the towel after "failing" with that?

HCV might not be a helpful template for the way the NASH market will play out. NASH is a multifactorial and poorly understood disease, while HCV is neither.

p.s. Viekira had peak annual sales of $1.5B (in 2015), so it was by no means a complete bust.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News